Aptar Digital Health, a specialist in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, is collaborating with Gerresheimer, a systems and solutions provider and partner to the pharma, biotech, and cosmetics industries, to develop a tailored solution to support patients and healthcare professionals in cancer therapy management.
By connecting Aptar Digital Health’s proprietary SaMD platform with Gx SensAir, Gerresheimer’s on-body device for the subcutaneous delivery of large biologics molecules, this solution is intended to improve overall treatment adherence and clinical outcomes. More specifically, it aims to make remote patient monitoring easier, and facilitate the onboarding of patients to new therapies, helping them to better manage adverse effects.
Sai Shankar, president of Aptar Digital Health, said: “We are honoured to collaborate with Gerresheimer, a global industrial partner in drug delivery devices. By combining our collective and proprietary expertise in device and software engineering, we believe this collaboration has the potential to deliver innovative solutions for patients, healthcare providers and the healthcare industry.”
Daniel Diezi, vice president digitalisation & new business models at Gerresheimer, added: “Combining our efforts opens up new exciting possibilities for optimising the respective drug therapy and improving the quality of life for cancer patients. This collaboration in oncology will lay the groundwork for Aptar Digital Health and Gerresheimer to potentially expand into other therapeutic areas in the future.”
This integrated solution will first be designed for targeted anti-cancer therapies with the potential to expand to all therapies delivered subcutaneously.